---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Co-prescribed/Concomitant therapies. Topics: Prior and current CIDP treatment permitted at entry to the phase 3 trial; Corticosteroids, immunosuppressants, and immunoglobulin during the phase 3 trial; Rescue therapy and return to standard of care in the phase 3 trial; Required vaccination against encapsulated bacteria in the phase 3 trial; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Prior and current CIDP treatment permitted at entry to the phase 3 trial

> “Must fulfill one of the following treatment conditions for CIDP:”
> “Currently treated with and responded to immunoglobulin (Ig) (intravenous immunoglobulin [IVIg] or subcutaneous immunoglobulin [SCIg]) alone or Ig (IVIg or SCIg) plus oral corticosteroids, or previously treated with and responded to, but are no longer being treated with (eg, lost access to), a maintenance regimen of Ig (IVIg or SCIg) alone or Ig (IVIg or SCIg) plus oral corticosteroids.”
> “Currently treated with and responded to oral corticosteroids alone or oral corticosteroids in combination with azathioprine or mycophenolate mofetil.”
> “Treatment naïve with no history of prior treatment for CIDP.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.12-2"></a>

### Corticosteroids, immunosuppressants, and immunoglobulin during the phase 3 trial

> “If applicable, oral corticosteroids (after tapering) and allowed immunosuppressants are continued in Parts A and B.”
> “For patients on IV or SC Ig, the last dose for both must occur 1 week prior to Day 1 of Part A.”
> “Patients who received complement inhibitors or anti-CD20 treatments within the previous 6 months are not eligible.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

> “Last dose of Ig and tapering of steroids completed 1 week prior to switching to claseprubart”
> “No requirement for washout or deterioration”

Source: [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3)

<a id="topic-2.1.2.12-3"></a>

### Rescue therapy and return to standard of care in the phase 3 trial

> “Additionally, patients who have a relapse in Part B (increase of ≥1 point in adjusted INCAT score) are also eligible for the OLE, including those who received Ig, corticosteroid, or PLEX rescue therapy.”
> “Patients can resume standard of care treatment for CIDP per the investigator’s judgment.”

Source: [Querol et al. (2026a)](https://investor.dianthustx.com/static-files/ad90264c-bc36-43e7-b977-a092dc30ab7b)

<a id="topic-2.1.2.12-4"></a>

### Required vaccination against encapsulated bacteria in the phase 3 trial

> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and vaccine availability.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.12-5"></a>

### Treatment at study entry: interim analysis of the first 40 participants

> “Most patients presented with typical CIDP with a mean (SD) time from diagnosis of 4.2 (6.1) years and were receiving immunoglobulins or oral corticosteroids at study entry (Table 1).”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

| Prior treatment group | Claseprubart 300 mg every 2 weeks (N=40), n (%) |
| --- | --- |
| Standard of care treated | “27 (67.5)” |
| Immunoglobulin | “19 (47.5)” |
| Oral corticosteroids | “8 (20.0)” |
| Standard of care refractory | “9 (22.5)” |
| Treatment naive | “4 (10.0)” |

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
